

~~Claim 23, line 1, delete "22", insert -- 20 -- .~~

~~Claim 23, line 1, delete "negative potentiator", insert -- gene of interest -- .~~

Claim 25 (amended) A method of selectively expressing a gene in a malignant cell comprising:

- C1
- (a) determining whether a malignant cell expresses sufficient levels of E2F to cause expression of a gene operably linked to an E2F responsive promoter;
  - (b) adding an effective amount of a nucleic acid cassette to the malignant cell that [you] was determined [expresses] to express sufficient E2F, wherein said nucleic acid cassette comprises an E2F responsive promoter [operable] operably linked to a gene of interest, wherein said gene [is a] encodes a protein that stimulates production or expression of a cellular product, a positive potentiator or encodes a gene that inhibits production or expression of a cellular product, a negative potentiator; [and]
  - (c) waiting until the nucleic acid cassette transduces the malignant cell; and [expresses]
  - (d) selectively expressing the gene by the E2F in said malignant cell causing the E2F responsive promoter to express said gene.

Please add the following claim:

C2  
-- 27. The method of claim 25, wherein the gene of interest is selected from the group consisting of cytokines or costimulatory molecules. --

#### REMARKS

In order to expedite prosecution, applicants have amended the claims. The amendments to claims 15, 18, 20, 21 and 23 are editorial in nature and clear from the context. The amendment to claim 25 is supported throughout this specification. See for example page 1 and 14-15. New claim 27 is supported by the specification of page 1. As such, these amendments do not constitute new matter and their entry is respectfully requested.

Applicants have amended the specification to specify certain compounds as trademarks and to provide their generic names, where appropriate. As such, these amendments do not constitute new matter and their entry is respectfully requested.